Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. [electronic resource]
Producer: 20120213Description: 1604-11 p. digitalISSN:- 1440-1746
- Adult
- Aged
- Aged, 80 and over
- Angiogenic Proteins -- blood
- Antineoplastic Agents -- adverse effects
- Benzenesulfonates -- adverse effects
- Biomarkers, Tumor -- blood
- Carcinoma, Hepatocellular -- blood
- Cytokines -- blood
- Disease-Free Survival
- Female
- Humans
- Japan
- Kaplan-Meier Estimate
- Liver Neoplasms -- blood
- Male
- Middle Aged
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Predictive Value of Tests
- Proportional Hazards Models
- Protein Kinase Inhibitors -- adverse effects
- Pyridines -- adverse effects
- Risk Assessment
- Risk Factors
- Sorafenib
- Survival Rate
- Time Factors
- Treatment Outcome
- Up-Regulation
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.